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Abstract
A growing body of literature has demonstrated the potential for ketamine in the treatment of
major depression. Sub-anesthetic doses produce rapid and sustained changes in depres-
sive behavior, both in patients and rodent models, associated with reorganization of gluta-
matergic synapses in the prefrontal cortex (PFC). While ketamine is known to regulate N-
methyl-D-aspartate (NMDA) -type glutamate receptors (NMDARs), the full complement of
downstream cellular consequences for ketamine administration are not well understood.
Here, we combine electrophysiology with 2-photon imaging and glutamate uncaging in
acute slices of mouse PFC to further examine how ketamine alters glutamatergic synaptic
transmission. We find that four hours after ketamine treatment, glutamatergic synapses
themselves are not significantly affected. However, levels of the neuromodulatory Regulator
of G-protein Signaling (RGS4) are dramatically reduced. This loss of RGS4 activity is asso-
ciated with disruption of the normal compartmentalization of synaptic neuromodulation.
Thus, under control conditions, α2 adrenergic receptors and type B γ-aminobutyric acid
(GABAB) receptors selectively inhibit α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) -type glutamate receptors (AMPARs) and NMDARs, respectively. After keta-
mine administration and reduction in RGS4 activity, this selectivity is lost, with both modula-
tory systems broadly inhibiting glutamatergic transmission. These results suggest a novel
mechanism by which ketamine may influence synaptic signaling and provide new avenues
for the exploration of therapeutics directed at treating neuropsychiatric disorders, such as
depression.
Introduction
Major depression, with a lifetime prevalence of 17%, presents a significant psychological and
economical burden for both individuals and society [1, 2]. Despite enormous efforts to develop
effective treatments, available therapeutic interventions have considerable limitations. For
example, most antidepressant medications take several weeks to achieve maximal benefit and a
significant fraction of patients remain refractory to treatment [3, 4]. However, recent studies
in both clinical and basic science fields have demonstrated promising results using low doses
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of the drug ketamine. Indeed, sub-anesthetic doses of ketamine produce rapid antidepressant
actions within a few hours [5–7], even in otherwise refractory patients [8]. Thus, the potential
benefits of this new pharmacological intervention provide great promise for the treatment of
major depression.
Surprisingly, the neurological mechanisms underlying the antidepressant actions of
ketamine remain poorly understood. Recent efforts have focused on the regulation of glutama-
tergic synapses in the prefrontal cortex (PFC) as a potential process by which ketamine modu-
lates behavior. Ketamine itself is an antagonist of N-methyl-D-aspartate (NMDA) -type
glutamate receptors (NMDARs) [9], though it may have other actions as well [10]. Acute
administration of ketamine produces mild dissociative effects that subside within two hours
after administration [11], while the antidepressant actions may persist for up to a week [5, 6].
In animal models, ketamine stimulates a signaling cascade that produces long-term enhance-
ment of glutamatergic transmission in the PFC, including increased synaptic protein synthesis
and increased density of dendritic spines, the structural sites of individual excitatory inputs
[12–15]. Moreover, these synaptic changes persist for several days after administration [13].
The cellular mechanisms underlying these alterations in synaptic structure and function are
unclear, and a variety of signaling pathways have been implicated in linking NMDAR blockade
to long-term alteration of glutamatergic signaling, including the mammalian target of rapamycin
(mTOR) and brain-derived neurotrophic factor (BDNF) [13, 16, 17]. Both these processes have
been shown to regulate the growth and stability of glutamatergic synapses [18, 19]. However,
ketamine has also been linked to alterations in inhibitory γ-aminobutyric acid (GABA) -ergic
signaling, both directly and indirectly by disrupting activity in inhibitory interneurons [20–22].
A recent study suggested that acute administration of ketamine might also impact the func-
tion of the protein regulator of G-protein signaling type-4 (RGS4) [23]. RGS4 is a GTPase
activating protein that accelerates the hydrolysis of guanosine-5’-triphosphate (GTP) to guano-
sine-5’-diphosphate (GDP) following the activation of G proteins by a variety of ligand-recep-
tor interactions [24, 25]. Behavioral studies in mice lacking RGS4 demonstrated that this
enzyme can act as a key negative modulator of ketamine-mediated antidepressant actions [23],
and ketamine itself is capable of reducing levels of RGS4 in the PFC. Previous studies found
that RGS4 plays a crucial role in regulating the neuromodulation of glutamatergic synapses in
the PFC [26]. These data showed that the specificity of adrenergic and GABAergic control over
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)- and NMDA-type glutamate
receptors, respectively, is abolished following pharmacological blockade of RGS4 function.
As neuromodulation may play a key role in normal prefrontal function, we investigated
whether ketamine might disrupt the regulation of glutamate receptors in the PFC. We used
whole-cell patch clamp electrophysiology and 2-photon calcium imaging in acute slices from
the mouse PFC to measure postsynaptic responses evoked by focal 2-photon glutamate uncag-
ing. We found that a single dose of ketamine did not alter basal function of postsynaptic gluta-
mate receptors. However, ketamine did produce a substantial reduction in prefrontal RGS4
levels in the PFC. We also found that 4 hours after ketamine treatment adrenergic and GABAer-
gic neuromodulators no longer displayed selectivity in the regulation of AMPA- and NMDA-
type glutamate receptors. Thus, our work suggests a novel mechanism by which acute ketamine
can influence glutamatergic signaling and potentially contribute to its antidepressant actions.
Materials and methods
Animals and drug treatment
All animal handling was performed in accordance with guidelines approved by the Yale and UC
Irvine Institutional Animal Care and Use Committee and federal guidelines. All experiments
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were approved by the above committees. Wild-type C57/Bl6 mice (postnatal day 22–42) of
either sex were injected i.p. with either saline vehicle or ketamine (15 mg/kg) 4 hours prior to
experiments.
Slice preparation
For glutamate uncaging experiments, we prepared acute prefrontal cortical (PFC) slices as pre-
viously described [26]. Briefly, mice were anesthetized with isoflurane and decapitated, and
coronal slices (300 μm) were cut in ice-cold solution containing (in mM): 110 choline, 25
NaHCO3, 1.25 NaH2PO4, 3 KCl, 7 MgCl2, 0.5 CaCl2, 10 glucose, 11.6 sodium ascorbate and
3.1 sodium pyruvate, bubbled with 95% O2 and 5% CO2. Slices containing the prelimbic-infra-
limbic regions of the PFC were then transferred to artificial cerebrospinal fluid (ACSF) con-
taining (in mM): 126 NaCl, 26 NaHCO3, 1.25 NaH2PO4, 3 KCl, 1 MgCl2, 2 CaCl2, 10 glucose,
0.4 sodium ascorbate, 2 sodium pyruvate and 3 myo-inositol, bubbled with 95% O2 and 5%
CO2. After an incubation period of 15 min at 34˚C, the slices were maintained at 22–24˚C for
at least 20 min before use.
Electrophysiology and imaging
All experiments were conducted at near physiological temperature (32–34˚C) in a submer-
sion-type recording chamber. Whole-cell recordings in voltage clamp mode were obtained
from layer 5 pyramidal cells (400–500 μm from the pial surface) identified with infrared differ-
ential interference contrast. Glass electrodes (1.8–3.0 MΩ) were filled with internal solution
containing (in mM): 135 CsMeSO3, 10 HEPES, 4 MgCl2, 4 Na2ATP, 0.4 NaGTP, 10 sodium
creatine phosphate and 0.2% Neurobiotin (Vector Laboratories) adjusted to pH 7.3 with
CsOH. Red-fluorescent Alexa Fluor-594 (10 μM, Invitrogen) and the green-fluorescent cal-
cium (Ca2+)-sensitive Fluo-5F (300 μM, Invitrogen) were included in the pipette solution.
Neurons were filled via the patch electrode for 10 min before imaging. Series resistance was
10–22 MΩ and uncompensated. Electrophysiological recordings were made using a Multi-
clamp 700B amplifier (Molecular Devices), filtered at 4 kHz, and digitized at 10 kHz. Typically,
7–10 trials were averaged into each response.
2-photon imaging was accomplished with a custom-modified Olympus BX51-WI micro-
scope (Olympus, Japan), including components manufactured by Mike’s Machine Company
[27]. Fluorophores were excited using 840 nm light from a pulsed titanium-sapphire laser
(Ultra2, Coherent). Emitted green and red photons were separated with appropriate optics
(Chroma, Semrock) and collected by photomultiplier tubes (Hamamatsu).
For Ca2+ imaging, signals were collected during 500 Hz line scans across a spine. Ca2+ sig-
nals were first quantified as increases in green fluorescence from baseline normalized to the
average red fluorescence (ΔG/R). We then expressed fluorescence changes as the fraction of
the G/R ratio measured in saturating Ca2+ (ΔG/Gsat)(Lur and Higley 2015).
2-Photon glutamate uncaging
For focal stimulation of single dendritic spines, we used 2-photon laser uncaging of glutamate
(2PLU). To photorelease glutamate, a second Ti-Sapphire laser tuned to 720 nm was intro-
duced into the light path using polarization optics. Laser power was calibrated for each spine
by directing the uncaging spot to the middle of the spine head. We adjusted uncaging power to
achieve 50% photobleaching of the Alexa 594 dye filling the spine [26]. The power used for
2PLU ranged from 8 to 25 mW, pulse duration was 0.5 ms. For synaptic stimulation, we typi-
cally uncaged glutamate at 3–4 separate locations around a single spine head to find a “hot
spot”, the place of the largest response. Our previous measurements indicate that this stimulus
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resulted in uncaging evoked excitatory post-synaptic currents (uEPSCs) similar in size and
kinetics to spontaneous miniature excitatory post-synaptic currents (uEPSCs) [26].
Data acquisition and analysis
Imaging and physiology data were acquired using National Instruments data acquisition
boards and custom software written in MATLAB (Mathworks, [28]). Off-line analysis was per-
formed using custom routines written in MATLAB and IgorPro (Wavemetrics). AMPAR-
mediated EPSC amplitudes were calculated by finding the peak of the current traces and aver-
aging the values within a 0.3 ms window. NMDAR-mediated currents were measured in a 3
ms window around the peak. 2PLU-evoked ΔCa2+ was calculated as the average ΔG/Gsat over
a 100 ms window, starting 5 ms after the uncaging event. Statistical comparisons were con-
ducted in GraphPad Prism 5. All data were analyzed using one-way analysis of variance
(ANOVA)-tests corrected for multiple comparisons (Tukey).
Pharmacology and reagents
2PLU experiments were performed in normal ACSF supplemented with MNI-glutamate (2.5
mM) and D-serine (10 μM). To isolate AMPAR-mediated currents in voltage clamp experi-
ments, we added tetrodotoxin (TTX) (1 μM) to block sodium channels, picrotoxin (50 μM) to
block GABAA receptors, CGP55845 (3 μM) to block GABAB receptors, and 3-(2-Carboxypi-
perazin-4-yl) propyl-1-phosphonic acid (CPP) (10 μM) to block NMDA-type glutamate recep-
tors to the ACSF. To isolate NMDAR-mediated currents, we modified our original ACSF to
contain 0 mM Mg and 3 mM Ca2+ and included TTX (1 μM), picrotoxin (50 μM), CGP55845
(3 μM), and 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX) (10 μM) to
block AMPA-type glutamate receptors. To activate α2 adrenergic receptors we used 40 μM
guanfacine (Tocris). The selective GABAB receptor agonist baclofen (Tocris), a drug primarily
used as a muscle relaxant, approved by the US Food and Drug Administration, was applied at
5 μM. Both G-protein coupled receptor (GPCR) agonists were applied 5–7 minutes prior to
data collection and remained in the bath for the duration of the experiment, but typically no
longer than 20 minutes to avoid receptor desensitization. All compounds and salts were from
Tocris and Sigma, respectively.
Western blot analysis
For RGS4 western blot analysis, we prepared 300 μm thick brain slices containing the PFC
from C57/bl6 mice as described above. Following the recovery period, the prelimbic region of
the prefrontal cortex was dissected out of the slices on ice. Tissue samples were homogenized
and sonicated in ice cold lysis buffer containing 20 mM Tris, 1 mM ethylenediaminetetraacetic
acid (EDTA) and 1x Halt protease and phosphatase inhibitor cocktail (Thermo Scientific) and
0.5% SDS, pH 8.0. After a 10-minute centrifugation at 14000 rpm, the supernatant was col-
lected, and protein content was determined using Pierce BCA Protein Assay (Thermo Scien-
tific). Samples containing equal amounts of protein were separated on a 6% poly-acrylamide
gel and transferred to polyvinylidene difluoride (PVDF) membranes. After blocking for 1h at
room temperature with 3% non-fat milk and 0.02% Na-azide in Tris buffered salt solution
with 0.05% Tween 20 (TBST), membranes were immunoreacted with a primary antibody
against RGS4 (Millipore, RBT17) [29] in 1% milk and 0.02% Na-azide in TBST, 1:1000, over-
night. After washing off excess primary antibody and incubation with the appropriate horse-
radish peroxidase (HRP) conjugated secondary antibody (GE Healthcare, UK) for 2 hours at
room temperature in TBST, bands were visualized using HyGlo Chemiluminescent HRP Anti-
body Detection Reagent (Denville Scientific Inc.) and exposed onto autoradiography film
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(Denville Scientific Inc.). Membranes were then stripped from antibodies using Restore
Plus Western Blot Stripping Buffer (15 minutes at room temperature, Thermo Scientific), re-
blocked and immunoreacted with anti-β-tubulin (SIGMA) primary antibody followed by the
appropriate HRP-secondary antibody to establish total amount β-tubulin in the samples. Auto-
radiography films were developed in a Kodak automatic developer, then scanned and analyzed
with ImageJ. RGS4 level was quantified as RGS4 / β-tubulin.
Behavioral analysis
To perform the forced swim test (FST) mice were individually placed in a transparent glass cyl-
inder (40 cm high, 20 cm diameter) containing 2000 ml of clear water at 24–26˚ C for 6 min.
Mice were not able to reach the top of the beaker or touch the bottom with their tail. A mouse
was judged to be immobile when it remained floating passively in the water. Using a video
recording, immobility time during the 4 last minutes of the test was measured post-hoc by two
independent investigators who were blinded to the animal’s condition. A decrease in immobil-
ity time indicates an antidepressant-like response.
For the light / dark box test (LDB) a standard mouse cage was split into two regions at the
2:1 ratio with a barrier that had a 5 x 5 cm gate to allow free movement between the chambers.
The smaller chamber (one third) was darkened. The apparatus was set up un a brightly lit test-
ing room. Animals were transferred to the dark side of an apparatus and their activity recorded
for 6 minutes. Two independent investigators, blinded to the animal’s condition, measured the
number of entries and the time spent in the brightly chamber post-hoc.
Behavioral experiments were conducted on 8 mice. On day 1 animals were injected with
saline vehicle at 10 am and tested in LDB and FST at 2–4 pm. After a day of rest, on day 3 mice
were injected with 15 mg/kg ketamine in saline at 10 am and re-tested in LDB and FST at 2–4
pm. It has been shown numerous times [30, 31] that 2 repeats of these test do not alter the ani-
mal’s performance. This design allowed us to perform paired statistics on the data while mini-
mizing animal sacrifice as per IACUC guidelines.
Results
Ketamine exerts no effect on NMDA receptors 4 hours post treatment
Previous works investigating the rapid onset antidepressant actions of ketamine in rodents
have placed the effective dose of ketamine between 5 and 50 mg/kg [13, 23, 32, 33]. To investi-
gate the consequences of ketamine for glutamatergic signaling, we injected mice with either a
single dose of ketamine (15 mg/kg) or saline vehicle. At four hours post-injection, we prepared
acute brain slices from the medial prefrontal cortex (PFC) of the injected animals and made
whole cell voltage clamp recordings from layer 5 pyramidal neurons in the prelimbic region
(Fig 1A). We measured excitatory postsynaptic currents (EPSCs) evoked by 2-photon laser
uncaging (2PLU) of glutamate onto spines along the basal dendrites, while simultaneously
monitoring intra-spine Ca2+ transients using 2-photon laser scanning microscopy (2PLSM)
(Fig 1B). We found no difference in AMPAR-mediated EPSCs between vehicle (20.9 ± 1.9 pA,
n = 31 spines) and ketamine (21.0 ± 1.4 pA, n = 33 spines, p = 0.96, t-test, Figs 1C and 4A)
groups. Notably, we also failed to observe alterations in NMDAR-mediated currents (vehicle:
22.9 ± 2 pA, n = 31 spines, ketamine: 21.4 ± 1.8 pA, n = 31 spines, p = 0.59, t-test, Figs 1C and
4B) or Ca2+ transients (vehicle: 0.52 ± 0.02 ΔG/Gsat, ketamine: 0.54 ± 0.02 ΔG/Gsat, p = 0.31, t-
test, Figs 1C and 4B), indicating the absence of persistent NMDAR blockade. Overall, our
results suggest that 4 hours post treatment, ketamine produces no change in postsynaptic glu-
tamate receptor responsiveness.
Ketamine disrupts synaptic neuromodulation
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Ketamine significantly reduces RGS4 expression in the PFC
To test whether ketamine administration results in reduced depression-like behaviors 4 hours
post-administration, we performed forced swim tests (FST). Ketamine treatment significantly
reduced immobility times compared to vehicle injection (p = 0.0034, n = 8, Paired t-test, Fig
2A). To further characterize the effect of ketamine we also measured the animal’s anxiety-like
behaviors using the light/dark box test (LDB). We found that vehicle and ketamine treated
mice spent the same amount of time in the brightly lit compartment (p = 0.64, n = 8, Paired t-
test Fig 2B) but ketamine injected mice achieved this in fewer gate crossings (p = 0.032, n = 8,
Paired t-test, Fig 2B), resulting in a significantly higher ratio between time spent in the light
compartment and the number of entries (p = 0.0013, n = 8, paired t-test, Fig 2B). These data
are in strong agreement with previous literature [13, 23, 32, 33], suggesting that 4 hours of
ketamine treatment results in reduced depression- and anxiety-like behaviors in mice.
Endogenous control of glutamatergic transmission by G-protein coupled receptors
(GPCRs) plays a central role in prefrontal function. Previous studies showed that both
Fig 1. Ketamine administration does not affect postsynaptic glutamate receptor activation 4 hours post
treatment. (A) A 2-photon image of a layer 5 pyramidal neuron visualized by Alexa 594 fluorescence. White
box highlights the extent of the basal dendritic arbor searched for spines. (Bi) Image of a dendritic spine. White
asterisk shows the uncaging location. Fluorescence intensity was measured in a line scan highlighted by the yellow
dashed line. (Bii) Chronogram showing the change in green fluorescence indicating a transient increase of intracellular
Ca2+ concentration in the spine head in response to glutamate uncaging (arrowhead). (Ci) Mean AMPAR-mediated
uEPSCs in vehicle (black) and in ketamine (blue) treated animals ± SEM (shaded areas). (Cii) 2PLU-evoked NMDAR
currents and (Ciii) Ca2+ transients in vehicle (black) and in ketamine treated animals (blue), mean (solid lines) ± SEM
(shaded areas). �: p<0.05, unpaired t-test.
https://doi.org/10.1371/journal.pone.0213721.g001
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noradrenergic and GABAergic modulation of glutamatergic synapses is influenced by the
activity of the small GTPase RGS4 [26], whose protein level is thought to be regulated by anti-
depressants including ketamine [23]. To examine the consequences of acute ketamine on
RGS4 function in the prefrontal cortex, we first prepared tissue samples from the prelimbic
region four hours after animals were injected with either ketamine or saline. Note that these
samples include both Layer 5 pyramidal neurons as well as additional excitatory and inhibitory
cells across all layers. Western-blot analysis confirmed a 50 ± 0.1% reduction of RGS4 protein
level (p = 0.0016, n = 5 animals, unpaired t-test, Fig 2C and 2D), suggesting that ketamine may
disrupt neuromodulation at glutamatergic synapses.
Reduced specificity of postsynaptic neuromodulation after ketamine
exposure
Activation of alpha2 adrenergic receptors and GABAB receptors negatively modulate AMPARs
and NMDARs, respectively via downregulation of protein kinase A (PKA) activity [26]. More-
over, this selective coupling of GPCRs to distinct synaptic proteins requires RGS4 and is lost
following small molecule antagonism of RGS4 activity [26]. We therefore asked whether keta-
mine produces similar dysregulation of synaptic modulation. First, we confirmed that, in
saline-injected mice, application of the alpha2 adrenergic agonist guanfacine significantly
reduced 2PLU-evoked AMPAR-mediated currents (to 13.0 ± 0.8 pA, n = 25 spines, one-way
ANOVA (F = 9.93, p<0.0001), Tukey’s multiple comparison test p<0.01, Figs 3Ai and 4A) but
Fig 2. Acute ketamine treatment decreases depression-like behavior and reduces prefrontal RGS4 levels. (A) Bars
show mean immobility times in forced swim test (FST). (B) Bar graph showing results of light / dark box test. Left:
mean time spent in the brightly lit compartment, middle: number of entries to the bright compartment, right: ration of
time spent in light and the number of entries. �: p< 0.05, paired t-test. (C) Example western blot of RGS4 and β-
tubulin in vehicle- versus ketamine- treated mice. (D) Quantification of RGS4 levels in vehicle (black) and ketamine
(blue) treated mice. Bars show mean ± SEM, �: p<0.05, unpaired t-test.
https://doi.org/10.1371/journal.pone.0213721.g002
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did not alter 2PLU-evoked NMDAR-mediated currents (22.3 ± 2 pA, n = 33 spines, one-way
ANOVA (F = 6.53, p = 0.0004), Tukey’s multiple comparison test p>0.05, Figs 3Aii and 4B) or
ΔCa2+ (0.54 ± 0.02 ΔG/Gsat, one-way ANOVA (F = 8.1, p<0.0001), Tukey’s multiple compari-
son test p>0.05, Figs 3Aiii and 4). Conversely, application of the GABAB agonist baclofen did
not alter 2PLU-evoked AMPAR-mediated currents (20.3 ± 1.5 pA, n = 32 spines, one-way
ANOVA (F = 10.3, p<0.0001), Tukey’s multiple comparison test p>0.05, Figs 3Bi and 4A) or
NMDAR currents (23.0 ± 2.5 pA, n = 25 spines, one-way ANOVA (F = 5.01, p = 0.0008),
Tukey’s multiple comparison test p>0.05, Figs 3Bii and 4B) but reduced NMDAR-dependent
ΔCa2+ (to 0.39 ± 0.01 ΔG/Gsat, one-way ANOVA (F = 12.11, p<0.0001), Tukey’s multiple
comparison test p<0.001, Figs 3Biii and 4C).
We then performed similar experiments in mice injected four hours prior to slice prepara-
tion with ketamine. In contrast to saline-treated animals, AMPAR-mediated currents were
significantly reduced by baclofen (to 12.1 ± 1 pA, n = 33 spines, one-way ANOVA (F = 9.93,
p<0.0001), Tukey’s multiple comparison test p<0.001, Fig 4Ai and 4B) while guanfacine sig-
nificantly reduced both NMDAR currents (to 13.6 ± 1.3 pA, n = 37 spines, one-way ANOVA
(F = 5.0, p = 0.0008), Tukey’s multiple comparison test p<0.05, Fig 4Aii and 4C) and ΔCa2+
(to 0.42 ± 0.02 ΔG/Gsat, one-way ANOVA (F = 12.1, p<0.0001), Tukey’s multiple comparison
test p<0.001, Fig 4Aiii and 4D). Previous studies showed that blocking RGS4 function does
not alter the effect of guanfacine on AMPARs or the baclofen induced reduction of NMDAR
dependent Ca2+ influx. This earlier work also showed that multiple methods of RGS4 inhibi-
tion introduced baclofen induced reduction of NMDAR currents (Lur et al, 2015). Our current
results match these previous observations. Overall, these findings show disrupted neuromodu-
lation of glutamatergic signaling in basal dendrites of layer 5 pyramidal neurons 4 hours after
ketamine administration but no direct actions on synaptic potency.
Fig 3. Differential control of excitatory transmission by α2- and GABAb receptors. (Ai) Mean AMPAR-mediated
uEPSCs in control (black) and guanfacine (orange) ± SEM (shaded areas). (Aii) 2PLU-evoked NMDAR currents and
(Aiii) Ca2+ transients in control (black) and guanfacine (orange), mean (solid lines) ± SEM (shaded areas). (Bi) Mean
AMPAR-mediated uEPSCs in control (black) and baclofen (magenta) ± SEM (shaded areas). (Bii) NMDAR-mediated
uEPSCs and (Biii) Ca2+ transients in control (black) and baclofen (magenta) ± SEM (shaded areas). �: p<0.05,
unpaired t-test.
https://doi.org/10.1371/journal.pone.0213721.g003
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Conclusions
In our present study, we demonstrate significant dysregulation of neuromodulatory control
over glutamatergic signaling in the mouse prefrontal cortex following the administration of
a single, sub-anesthetic dose of ketamine. Specifically, following ketamine administration,
adrenergic and GABAergic receptor activation inhibits NMDARs and AMPARs, respectively,
a phenomenon that does not occur in untreated animals. Our results suggest this process may
be mediated by acute reduction in levels of the small GTPase RGS4, which were previously
shown to prevent neuromodulatory cross-talk in dendritic spines [26]. Our findings thus
extend our knowledge of targets for ketamine that may contribute to or interact with its anti-
depressant actions in vivo.
G-protein coupled receptors (GPCRs) provide a ubiquitous mechanism for regulating syn-
aptic transmission via neuromodulators like norepinephrine, GABA, serotonin, dopamine
and adenosine. Despite their vast capacity to distinguish extracellular ligands, GPCR activation
may engage only a handful of intracellular signaling cascades, many of which rely on soluble,
small molecule second messenger systems. In theory, the paucity of unique intracellular
response pathways and the high mobility of second messengers could severely limit the sys-
tem’s capacity for selective regulation. This would be increasingly true for small volume cellu-
lar compartments like the dendritic spine. Our previous work showed that within a single
synapse, distinct glutamate receptor subtypes (AMPA and NMDA receptors) are selectively
regulated by α2 adrenoreceptors and GABAB receptors, respectively, despite being coupled to
Fig 4. Ketamine treatment eliminates compartmentalized neuromodulation. (Ai) Mean AMPAR-mediated uEPSCs in control (black) and baclofen
(magenta) ± SEM (shaded areas). (Aii) 2PLU-evoked NMDAR currents and (Aiii) Ca2+ transients in control (black) and guanfacine (salmon), mean
(solid lines) ± SEM (shaded areas). (B) Bars represent mean amplitude ± SEM of AMPAR currents, (C) NMDAR-mediated currents and (D) NMDAR-
mediated Ca2+ transients in control (gray), in guanfacine (orange) or in baclofen (magenta) from vehicle- versus ketamine-treated mice. Ctr: control,
GF: guanfacine treatment, Bac: baclofen treatment, Veh: vehicle injected, Ket: ketamine injected. �: p<0.05, Tukey’s multiple comparison test.
https://doi.org/10.1371/journal.pone.0213721.g004
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identical second messenger pathways. We showed that this segregation was possible due to the
establishment of synaptic microdomains through the actions of RGS4. In general, this mecha-
nism allows the close coexistence and nuanced function of neuromodulatory systems.
RGS4 is a small GTPase that limits signaling through G protein-coupled receptor pathways
by accelerating the hydrolysis of GTP to GDP [24, 34, 35]. Under control conditions, this activ-
ity produces microdomains within single dendritic spines that restricts neuromodulatory cas-
cades. For example, adrenergic α2 receptors and GABAB receptors are both coupled to Gi
proteins that down-regulate cAMP production and PKA activity. Surprisingly, we found
that both receptors are present in single spines but are selectively able to negatively modulate
AMPARs and NMDARs, respectively [26]. However, when RGS4 is blocked pharmacologi-
cally, this microdomain organization breaks down, leading to cross talk between the neuromo-
dulatory signaling cascades [26, 35]. Remarkably, a single dose of ketamine appears to produce
substantial loss of RGS4 within a few hours [23], a finding confirmed in our present study, sug-
gesting this protein is rapidly turned over in cortical neurons. Consistent with our previous
results using small molecule inhibitors of RGS4, ketamine-induced down-regulation of RGS4
is associated with aberrant cross-talk between modulatory signals and glutamate receptors.
While these results are strongly suggestive, it will be necessary in future studies to experimen-
tally restore RGS4 to control levels to directly confirm causal links between ketamine, RGS4
signaling, and synaptic modulation.
Previous studies looking at the effects of ketamine administration 24 hours post-exposure
showed increased frequency for pharmacologically evoked EPSCs in layer 5 PNs. This result
was linked to an increase in both spine volume and the density of mature spines and attributed
to changes in postsynaptic gene expression [13]. Others have found increased NMDAR EPSC
amplitudes at the 24-hour time point [36]. In contrast, our results indicate that four hours
after ketamine administration basal postsynaptic glutamatergic signaling through either
AMPARs or NMDARs is unaltered. This difference may be due to a longer time window
required for altered synaptic gene expression to manifest. Additionally, changes in pharmaco-
logically evoked EPSCs are difficult to interpret, as pre- or postsynaptic alterations cannot be
distinguished. Importantly, we demonstrate behavioral effects of ketamine commensurable
with previous findings [13, 23, 32, 33, 37].
Acute doses of ketamine have been shown to produce rapid synaptic reorganization in the
prefrontal cortex that coincides with antidepressant actions in rodent models [21, 38]. Interest-
ingly, these effects are thought to be mediated through inhibition of NMDARs by ketamine
[38]. This hypothesis is supported by evidence that other NMDAR blockers can produce
similar synaptic and behavioral effects [17, 38]. Loss of NMDAR signaling may activate both
mTOR and BDNF signaling pathways that may provide molecular mechanisms for synaptic
changes following ketamine [13, 16–19, 33]. To ensure compatibility with these previous
results we also directed our recordings to the medial PFC. We focused our efforts on layer 5
pyramidal neurons because this cell population generates the majority of the synaptic output
of the neocortex. Our findings suggest the intriguing possibility that ketamine may also sup-
press NMDAR activity by broadening the consequences of adrenergic signaling, even after the
NMDAR antagonistic effect of ketamine faded. That is, following ketamine, α2 receptors may
further suppress these glutamate receptors. Thus, activation of adrenergic signaling could be
an adjunct approach to boost the effects of ketamine. Indeed, guanfacine alone exhibits antide-
pressant activity in rodents [39, 40].
In conclusion, our current findings provide novel evidence that acute ketamine can influ-
ence glutamatergic transmission in the mouse prefrontal cortex, potentially via down-regula-
tion of RGS4 and dysregulation of neuromodulatory signaling. These results expand our view
of the possible downstream actions of ketamine and suggest that inhibition of NMDARs by α2
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adrenergic signaling may provide benefit in models of depression when delivered alongside
sub-anesthetic doses of ketamine. Pending further experimental confirmation, our results
may advance the clinical application of ketamine in the treatment of depression and anxiety
disorders.
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